Helen M. Parry, MBChB, PhD

Associate Professor
University of Birmingham, United Kingdom

Helen is an Associate Professor at University of Birmingham and MRC/BCUK Clinician Scientist. Her lab focusses on understanding immune deficiency in blood cancer patients and studying vaccine immunity. She also works as an Honorary Consultant Haematologist at University Hospitals Birmingham where she is chief investigator on several CLL trials

Poster(s):

• 1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

• 1223 - Depletion of normal B-cells, defined as < 20 cells/µL by high-sensitivity analysis, identifies early-stage CLL and MBL patients at increased risk of severe infection and early mortality.

• 1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.

• 1713 - An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.